Danaher (NYSE:DHR) PT Raised to $270.00 at Bank of America

Danaher (NYSE:DHR) had its target price increased by research analysts at Bank of America from $258.00 to $270.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the conglomerate’s stock. Bank of America‘s target price would suggest a potential upside of 7.83% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Robert W. Baird increased their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday. Barclays boosted their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Royal Bank of Canada boosted their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. KeyCorp increased their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, TD Cowen lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $269.38.

Danaher Stock Down 1.1 %

NYSE:DHR traded down $2.72 during midday trading on Wednesday, reaching $250.39. The company had a trading volume of 1,285,176 shares, compared to its average volume of 2,757,865. The stock’s fifty day simple moving average is $248.95 and its 200-day simple moving average is $230.64. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00. The firm has a market capitalization of $185.42 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 3.96 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the previous year, the company posted $2.36 earnings per share. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, sell-side analysts anticipate that Danaher will post 7.62 earnings per share for the current fiscal year.

Insider Activity

In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Teri List sold 3,289 shares of Danaher stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 over the last quarter. Corporate insiders own 10.90% of the company’s stock.

Institutional Trading of Danaher

A number of hedge funds have recently added to or reduced their stakes in the business. Tsfg LLC increased its position in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. Cape Investment Advisory Inc. purchased a new position in shares of Danaher in the 4th quarter valued at $25,000. BKM Wealth Management LLC acquired a new position in shares of Danaher during the 4th quarter valued at $27,000. Redmont Wealth Advisors LLC purchased a new position in Danaher in the first quarter valued at about $30,000. Finally, Wetzel Investment Advisors Inc. purchased a new position in Danaher in the fourth quarter valued at about $29,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.